Marksans Pharma Ltd

NSE: MARKSANS · BSE: 524404 · Pharmaceuticals & Biotechnology · 10 announcements

Share price: ₹336.95
Market cap: ₹15,269 Cr
Revenue (annual): ₹2,951 Cr
Net profit (annual): ₹417.9 Cr
P/E (TTM): 29.6×Sector 50.4×
Promoter holding: 43.87%+0.00% QoQ
FII holding: 17.47%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 2 Promoter Selling (Off-Market) 1 Other Announcement 1 Financial Results 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

20 Aug 2026 11:42 IST BSE

Earnings Call

Marksans Pharma Investor Presentation: Key Takeaways

Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.

Call: Guides 20% growth

Open call summary → Read the filing ↗

3 Aug 2026 18:38 IST NSE

Earnings Call

Marksans Pharma Earnings Call Transcript: Key Takeaways

Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.

Call: Guides 20% growth

Open call summary → Read the filing ↗